Abstract 1682P
Background
Advanced PDAC carries a dismal prognosis with a 5-year survival rate of 3%. While treated as an even population, previous retrospective studies suggested significant different survival rates for patients (pts) with lung-only metastases (mets) when compared to other pts. This study aims to explore prospectively the difference in survival outcome based on initial site of metastases in synchronous metastatic PDAC.
Methods
This is a prospective observational study including all adult pts with synchronous metastatic PDAC in BACAP (national Anatomo-Clinical Database on Pancreatic Adenocarcinoma). Data regarding pts demographics, tumor characteristics, and survival outcomes were analyzed. Primary endpoint was overall survival (OS), defined as the time from diagnosis to death or most recent follow-up.
Results
Overall, 504 pts were included [52.4% male, mean age 69 years] of which 31 (6.2%), 58 (11.5%), 363 (72%) and 51 (10.1%) pts had lung-only, peritoneal-only, liver-only and multi-site mets at diagnosis, respectively. Most patients (79.2%) received at least one line of chemotherapy. Patients with lung-only mets were older (38.7% were > 75 years old), mostly male (61.3%) and 22.6% received at least 3 lines of chemotherapy (vs 15.5% for other patients). Median OS was significantly different according to mets site (p=0.003) (Table), with a trend towards better PFS when lung-only mets: 6.3 vs 5.4, 4.5 and 2.4 mo when peritoneal-only, liver-only and multi-site mets, respectively (p=0188).
Table: 1682P
Group | N | Event (%) | OS (mo) | 95% CI |
Lung-only | 29 | 25 (86.2) | 11.7 | [9.3; 14.6] |
Peritoneal-only | 58 | 49 (84.5) | 9.2 | [5.5; 12.9] |
Liver-only | 362 | 334 (92.3%) | 7.2 | [6.1; 8.1] |
Multi-site | 52 | 50 (96.2%) | 4.1 | [2.3; 5.0] |
Total | 501 | 458 (91.4%) | 7.2 | [6.1 ;8.1] |
p=0.003
Conclusions
Pts with lung-only mets represented 6.2% of synchronous metastatic PDAC pts and exhibited improved survival. These results suggest that a subset of pts with synchronous metastatic PDAC could benefit from more aggressive locoregional treatments. Underlying biological mechanisms contributing to survival difference are under investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1676P - Clinical outcomes of first-line chemotherapy in locally advanced and metastatic pancreatic adenocarcinoma patients: Real-world experience
Presenter: Nunticha Umpawan
Session: Poster session 22
1677P - Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma
Presenter: Daniele Lavacchi
Session: Poster session 22
1678P - A retrospective real-world study of nimotuzumab combined with chemotherapy for first-line treatment of advanced pancreatic cancer: A single center propensity score matched analysis
Presenter: Yinying Wu
Session: Poster session 22
1679P - Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: A systematic review and network meta-analysis
Presenter: Luca Mastrantoni
Session: Poster session 22
1680P - Meta-analysis of real-world survival outcomes of liposomal irinotecan in advanced pancreatic cancer patients with prior irinotecan exposure
Presenter: Amol Gupta
Session: Poster session 22
1681P - A retrospective real-world study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer
Presenter: Siyi Zou
Session: Poster session 22
1683TiP - Trial in progress: NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer-NEO-IMPACT
Presenter: Sarah Maloney
Session: Poster session 22
1684TiP - PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
Presenter: Philippe Cassier
Session: Poster session 22
1685TiP - Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): A multicenter randomized controlled trial
Presenter: Jacob van Dam
Session: Poster session 22
1686TiP - Olaparib and durvalumab (MEDI4736) phase II study in patients with metastatic pancreatic cancer and DNA damage repair genes alterations
Presenter: Teresa Macarulla
Session: Poster session 22